Cargando…

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma

Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved for treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in glioblastoma comprise alternating electric fields (200 kHz) delivered continuously, ideally for ≥18 h/day, to the tumor bed via t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacouture, Mario E., Anadkat, Milan J., Ballo, Matthew T., Iwamoto, Fabio, Jeyapalan, Suriya A., La Rocca, Renato V., Schwartz, Margaret, Serventi, Jennifer N., Glas, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399624/ https://www.ncbi.nlm.nih.gov/pubmed/32850308 http://dx.doi.org/10.3389/fonc.2020.01045

Ejemplares similares

Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region
por: Anadkat, Milan J., et al.
Publicado: (2023)

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
por: Lacouture, Mario E., et al.
Publicado: (2020)

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
por: Lacouture, Mario E., et al.
Publicado: (2017)

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)
por: Shi, Wenyin, et al.
Publicado: (2022)

Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events
por: Ciccolini, Kathryn, et al.
Publicado: (2017)

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
por: Lacouture, Mario E., et al.
Publicado: (2011)

Management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma multiforme: A 27-case series
por: Chen, Xiaoxue, et al.
Publicado: (2022)

Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic
por: Gatson, Na Tosha N., et al.
Publicado: (2021)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
por: Tischer, Bernd, et al.
Publicado: (2016)

Management of Dermatologic Toxicities Associated With Targeted Therapy
por: Lacouture, Mario E.
Publicado: (2016)

Integration of Tumor‐Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies
por: Wang, Yuefeng, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
por: Lacouture, Mario E, et al.
Publicado: (2022)

Online tool for monitoring adverse events in patients with cancer during treatment (eRAPID): field testing in a clinical setting
por: Warrington, Lorraine, et al.
Publicado: (2019)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

Enhancing glioblastoma treatment through the integration of tumor-treating fields
por: Szklener, Katarzyna, et al.
Publicado: (2023)

Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS
por: Masucci, Chiara, et al.
Publicado: (2023)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists
por: Zahedi Niaki, Omid, et al.
Publicado: (2020)

Characteristics and management of tumor treating fields-related dermatological complications in patients with glioblastoma
por: Yang, Chao, et al.
Publicado: (2023)

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
por: Yang, Ruoning, et al.
Publicado: (2022)

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
por: Robins, H. Ian, et al.
Publicado: (2018)

Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
por: Palmer, Joshua D., et al.
Publicado: (2021)

Research on application of tumor treating fields in glioblastoma: A bibliometric and visual analysis
por: Du, Xue, et al.
Publicado: (2022)

Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
por: Vymazal, Josef, et al.
Publicado: (2023)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Venous thromboembolic events in glioblastoma patients: An epidemiological study
por: Eisele, Amanda, et al.
Publicado: (2022)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Baseline risk factors associated with immune related adverse events and atezolizumab
por: Madjar, Katrin, et al.
Publicado: (2023)

COVD-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE
por: Tosha Gatson, Na, et al.
Publicado: (2020)

Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel()()
por: Cury-Martins, Jade, et al.
Publicado: (2020)

High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022)

A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
por: Parisi, Rose, et al.
Publicado: (2023)

Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
por: Liu, Ya, et al.
Publicado: (2021)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: O’Brien, Susan M., et al.
Publicado: (2021)

Classification of Adverse Events Following Surgery in Patients With Diffuse Lower-Grade Gliomas
por: Gómez Vecchio, Tomás, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3f1jndkpnbaoffkibq2s83muke